Exogenous LEAP2 hormone: This intervention has never been examined in this type of study before.
Study summary
The naturally occurring hormone LEAP2 is proposed to have opposite effects to that of the 'hunger hormone' ghrelin. Other that appetite regulation, LEAP2 is involved in glucose metabolism through mechanisms yet not fully understood. With two experimental days; one recieving LEAP2 and one recieving placebo infusion in a randomized order, the study will explore the effect of LEAP2 (vs. placebo) on glucose metabolism through total-body PET/CT-scans and thereby gain a deeper understanding of the ghrelin/LEAP2 system and its interaction with glucose metabolism. Furthermore, the project will generate scanning references in individuals with obesity that are usable in forthcoming research projects.
Eligibility
Sex
MALE
Min age
18 Years
Max age
60 Years
Healthy volunteers
Accepted
Inclusion Criteria:
* Caucasian
* Age between 18 and 60 years at the time of inclusion
* Body mass index 30-50 kg/m2
* Informed consent
Exclusion Criteria:
* Anaemia (haemoglobin below normal range)
* Alanine aminotransferase (ALAT) and/or aspartate aminotransferase (ASAT) ≥2 times normal values) or present hepatobiliary and/or gastrointestinal disorder(s)
* Nephropathy (serum creatinine above normal range and/or albuminuria)
* Glycated haemoglobin (HbA1c) ≥48 mmol/mol and/or type 2 diabetes requiring medical treatment
* Regular tobacco smoking or use of other nicotine-containing products
* Claustrophobia
* Any ongoing medication that the investigator evaluates would interfere with trial participation.
* Any physical or psychological condition that the investigator evaluates would interfere with trial participation including any acute or chronic illnesses
Primary outcome measure(s)
Change in in hepatic MRglu (metabolic rate of glucose) — During PET-scan (From time 75 minutes to 145 minutes) The primary endpoint is the change in hepatic MRglu (metabolic rate of glucose) assessed with total-body PET/CT technique, which will be compared between the two experimental days with infusion of placebo and LEAP2, respectively
Trial sites (1)
Facility
City
Region
Status
Center for Clinical Metabolic Research, Gentofte Hospital
Hellerup
Capital Region
More University Hospital, Gentofte, Copenhagen trials in Denmark
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.